{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:49:38Z","timestamp":1789566578488,"version":"build-2803163510"},"reference-count":43,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"26","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,9,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Brain metastases (BMs) of triple-negative breast cancer (TNBC) are lethal, often associated with a limited life span and lack of effective antitumor agents. Here we reported a triple combination therapy consisting of adebrelimab, bevacizumab, and cisplatin\/carboplatin in BMs of TNBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This phase II clinical trial involved patients with TNBC with active BMs. Participants were administered with adebrelimab, bevacizumab, and cisplatin\/carboplatin until disease progression or unacceptable toxic effects. The primary end point was the objective response rate in CNS (CNS-ORR) according to the Response Assessment in Neuro-Oncology BMs criteria, and the secondary end points included the clinical benefit rate in CNS (CNS-CBR), progression-free survival (PFS), overall survival (OS), the first progression site, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 35 patients were enrolled and treated, and the median lines of previous treatment were 2 (range, 0-4). The confirmed CNS-ORR was 77.1% (27\/35, 95% CI, 59.9 to 89.6), and the CNS-CBR was 80.0% (28\/35, 95% CI, 63.1 to 91.6). The median overall PFS was 8.3 months (95% CI, 5.8 to 11.5), whereas the median CNS-PFS was 10.3 months (95% CI, 7.4 to 14.3) and the median OS was 21.1 months (95% CI, 13.2 to not reached). Among the 28 patients who progressed, progression was intracranial-only in 32.1% (9\/28) patients, extracranial-only in 35.7% (10\/28) patients, and both in 32.1% (9\/28) patients. The incidence of grade \u22653 treatment-related adverse events was 65.7% (23\/35). Treatment-related serious adverse events occurred in five patients (14.3%), and no treatment-related deaths were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The combination of adebrelimab, bevacizumab, and cisplatin\/carboplatin was the first regimen to demonstrate promising intracranial antitumor activity and prolonged PFS and CNS-PFS, along with a manageable safety profile, warranting further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-02021","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T20:59:49Z","timestamp":1772657989000},"page":"2543-2553","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":1,"title":["Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin\/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)"],"prefix":"10.1200","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct04303988","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8350-864X","authenticated-orcid":true,"given":"Teng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3975-3803","authenticated-orcid":true,"given":"Zhonghua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5429-0248","authenticated-orcid":true,"given":"Chengcheng","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotao","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jin","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-699X","authenticated-orcid":true,"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3208-3106","authenticated-orcid":true,"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China"},{"name":"Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_12_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01296-5"},{"key":"e_1_3_12_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa285"},{"key":"e_1_3_12_4_2","first-page":"1","article-title":"Central nervous system metastases from triple-negative breast cancer: Current treatments and future prospective","volume":"14","author":"Kadamkulam Syriac A","year":"2022","unstructured":"Kadamkulam Syriac A, Nandu NS, Leone JP: Central nervous system metastases from triple-negative breast cancer: Current treatments and future prospective. Breast Cancer 14:1-13, 2022","journal-title":"Breast Cancer"},{"key":"e_1_3_12_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2697-2"},{"key":"e_1_3_12_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33243"},{"key":"e_1_3_12_7_2","unstructured":"National Comprehensive Cancer Network: Central nervous system cancers. 2024"},{"key":"e_1_3_12_8_2","unstructured":"National Comprehensive Cancer Network: Breast cancer. 2025"},{"key":"e_1_3_12_9_2","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-24-31"},{"key":"e_1_3_12_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202809"},{"key":"e_1_3_12_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02677-x"},{"key":"e_1_3_12_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_12_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_12_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03630-w"},{"key":"e_1_3_12_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.554"},{"key":"e_1_3_12_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03261-7"},{"key":"e_1_3_12_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0391-x"},{"key":"e_1_3_12_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02820-9"},{"key":"e_1_3_12_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5456"},{"key":"e_1_3_12_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01372-w"},{"key":"e_1_3_12_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01891"},{"key":"e_1_3_12_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00224-8"},{"key":"e_1_3_12_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102795"},{"key":"e_1_3_12_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100853"},{"key":"e_1_3_12_25_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0982"},{"key":"e_1_3_12_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01536-6"},{"key":"e_1_3_12_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_3_12_28_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005835430489"},{"key":"e_1_3_12_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3039-y"},{"key":"e_1_3_12_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1081"},{"key":"e_1_3_12_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103209"},{"key":"e_1_3_12_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103699"},{"key":"e_1_3_12_33_2","first-page":"1638","article-title":"Activity of capecitabine for central nervous system metastases from breast cancer","volume":"17","author":"Gouveia MC","year":"2023","unstructured":"Gouveia MC, Hidalgo Filho CM, Moreno RA, et al: Activity of capecitabine for central nervous system metastases from breast cancer. Ecancermedicalscience 17:1638, 2023","journal-title":"Ecancermedicalscience"},{"key":"e_1_3_12_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.565"},{"key":"e_1_3_12_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1694"},{"key":"e_1_3_12_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.299"},{"key":"e_1_3_12_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS20-PD13-07"},{"key":"e_1_3_12_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01114-w"},{"key":"e_1_3_12_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_12_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.001"},{"key":"e_1_3_12_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.002"},{"key":"e_1_3_12_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70064-1"},{"key":"e_1_3_12_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.600"},{"key":"e_1_3_12_44_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061451"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:59:31Z","timestamp":1788559171000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":43,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026,9,10]]}},"alternative-id":["10.1200\/JCO-25-02021"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02021","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"2025-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}